Vision Financial Markets’s AYTU BioPharma AYTU Stock Holding History

Vision Financial Markets’s Portfolio AYTU Stock Details AYTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6	Hold	2	–	–	﹤0.01%	422
2025 Q4	$6	Hold	2	–	–	﹤0.01%	406
2025 Q3	$4	Hold	2	–	–	﹤0.01%	429
2025 Q2	$5	Hold	2	–	–	﹤0.01%	433
2025 Q1	$3	Buy	+2	New	+$3	﹤0.01%	435

Other funds holding AYTU

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

CAM

Crown Advisors Management Larkspur, California $151M AUM 73.11% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PAP

Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vision Financial Markets's AYTU Position: Q1 2026 in Review

Vision Financial Markets held its AYTU BioPharma (AYTU) position steady in Q1 2026 at 2 shares worth $6. The position accounts for ﹤0.01% of the portfolio, ranked #422.

Vision Financial Markets first reported a position in AYTU in Q1 2025 and has held it in 5 quarters since. 37 funds tracked by Wall St. Rank hold AYTU as of Q1 2026.

Vision Financial Markets held 2 shares of AYTU BioPharma worth $6 as of Q1 2026.
Vision Financial Markets left its AYTU BioPharma share count unchanged in Q1 2026.
AYTU BioPharma made up ﹤0.01% of Vision Financial Markets's portfolio in Q1 2026, its #422 holding.
Vision Financial Markets first reported a position in AYTU BioPharma in Q1 2025 and has held it in 5 quarters since.
37 funds tracked by Wall St. Rank held AYTU BioPharma as of Q1 2026.

Based on Vision Financial Markets's 13F filing for Q1 2026, filed 24 Apr 2026.